If you have been reading about somatotroph and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-10-30. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | Matches human GHRH(1-44) length |
| N-terminal modification | trans-3-hexenoyl group | Confers resistance to dipeptidyl peptidase IV |
| Appearance | White to off-white powder | Typically supplied lyophilized in a sealed vial |
| Solubility class | Freely soluble in water | Hydrophilic peptide; polar solvent compatible |
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
== Disorders == Platelet disorders can occur because there are not enough platelets, too many platelets, or the platelets do not function properly. Low platelet concentration is called thrombocytopenia, and is due to either decreased production, increased destruction of platelets, or platelets being sequestered in another part of the body. Elevated platelet concentration is called thrombocytosis, and is either congenital, reactive (to cytokines), or due to unregulated production: one of the myeloproliferative neoplasms or certain other myeloid neoplasms. Normal platelets can respond to an abnormality on the vessel wall rather than to hemorrhage, resulting in inappropriate platelet adhesion/activation and thrombosis: the formation of a clot within an intact vessel. This type of thrombosis arises by mechanisms different from those of a normal clot: extending the fibrin of venous thrombosis; extending an unstable or ruptured arterial plaque, causing arterial thrombosis; and microcirculatory thrombosis. An arterial thrombus may partially obstruct blood flow, causing downstream ischemia, or may completely obstruct it, causing downstream tissue death.:
Everything the intelligentsia had ever hoped for in terms of freedom of expression and publication was suddenly available. Thanks to glasnost, the Soviet press was full of informed, detailed criticisms of historical ‘mistakes’ such as collectivization, the Great Purges, bad decisions in World War II, wartime ethnic deportations and postwar anti-Semitism. Newspapers and thick journals competed with each other for exposés, publishing all the manuscripts in drawers that had hitherto been forbidden and pushing for rehabilitation of fallen revolutionary heroes. It was a wonderful time to be a Soviet writer of a certain age and type—a Khrushchevian truth-teller whose realist novels and plays unmasked social ills, historical cover-ups and political scandals. It was an equally exciting time to be a Soviet reader, except that there was too much to read, and what one read was likely to shake one's faith in the Soviet system. Gorbachev's assumption, like that of the old reform-minded thick journals, was that 'telling the truth' could not but be good, ultimately strengthening the Soviet system by purifying it. Unfortunately, the opposite proved to be the case. The effect of the crash course on the flaws of Soviet socialism was to undermine the public’s confidence rather than rally it for reform. Additionally, the internal political reforms associated with perestroika altered both the political consciousness of Soviet society and the strategic outlook of Soviet foreign policy.
In Trump's first hundred days in office, he signed 143 executive orders, the most of any president in this period, 42 presidential memoranda, 42 presidential proclamations, the Laken Riley Act, a continuing appropriations act, and other pieces of legislation for Congress. Trump's extensive use of executive orders drew a mixed reception from both Republicans and Democrats. Some executive orders tested the limits of executive authority, and others faced immediate legal challenges. Major topics Trump focused on included immigration reform, deportations, applying tariffs on other countries, cutting federal spending, reducing the federal workforce, increasing executive authority, and implementing a non-interventionist foreign policy.
Sources: en.wikipedia.org
=== Peptide tags === Short tags on proteins are more commonly called "epitope tags." The tags on this list would fall under that category. "Epitope tagging" is the process of adding a short peptide to a protein such that it can be detected using an antibody specific to that peptide (epitope).
These two are the heaviest isotopes of dubnium to date, and both were produced as a result of decay of the heavier nuclei 288Mc and 294Ts rather than directly, because the experiments that yielded them were originally designed in Dubna for 48Ca beams. For its mass, 48Ca has by far the greatest neutron excess of all practically stable nuclei, both quantitative and relative, which correspondingly helps synthesize superheavy nuclei with more neutrons, but this gain is compensated by the decreased likelihood of fusion for high atomic numbers.
This characteristic distinguishes the C5 step, along with the C2 step, as potentially rate-limiting in the complement reaction. However, unlike C2, C5 remains firmly cell-bound during the decay process and apparently undergoes an alteration in situ which renders it hemolyticly unreactive. Finally, C5 is unique in that it readily adsorbs in native form to unsensitized erythrocytes. This nonspecifically bound C5 remains firmly attached, although it may be specifically utilized as a source of C5 by an ongoing complement reaction.
Sources: en.wikipedia.org
=== Infertility === It can be difficult to become pregnant with PMOS due to irregular ovulation. The first management step is to improve the general health of the mother, such as through lifestyle interventions. GLP-1 agonist for weight loss can be used, but should be stopped at least 2 months before conception. As of 2025, there is not enough data to know if they are safe in pregnancy. Pregnancy in PMOS is more risky than normal, and treatment is focused on getting a single pregnancy, rather than, for instance, twins (multiple pregnancy). With treatment, the eventual family size of women with PMOS does not seem different to those without. The first-line medical treatment for infertility in women with PMOS is letrozole (Femara) to induce ovulation. This is, in general, more effective than clomiphene citrate to improve both pregnancy rates and live births. Other medications that can be used to treat infertility, listed from most to least effective, are metformin + clomiphene citrate, clomiphene citrate alone, and metformin alone. Women may be more likely to experience gastrointestinal side effects with metformin. Gonadotrophin therapy may be effective too, but requires monitoring and increases the risks of multiple pregnancies. When medication and lifestyle interventions are ineffective, infertility can be treated with a laparoscopic procedure called "ovarian drilling", which involves puncture of 4–10 small follicles with electrocautery, laser, or biopsy needles.
Now that they had a mould that grew well submerged and produced an acceptable amount of penicillin, the next challenge was to provide the required air to the mould for it to grow. This was solved using an aerator, but aeration caused severe foaming of the corn steep. The foaming problem was solved by the introduction of an anti-foaming agent, glyceryl monoricinoleate. The technique also involved cooling and mixing.
"It really got to them," recalls Dr. William Schneider Jr., [former] undersecretary of state for military assistance and technology, who saw classified "after-action reports" that indicated U.S. flight activity. "They didn't know what it all meant. A squadron would fly straight at Soviet airspace, and other radars would light up and units would go on alert. Then at the last minute the squadron would peel off and return home." From the accounts of CIA and senior KGB officers, by May 1981, obsessed with historical parallels with the 1941 German invasion and Reaganite rhetoric, and with no defensive capability against the Pershing IIs, Soviet leaders believed the United States was preparing a secret nuclear attack on the USSR and initiated Operation RYaN. Under this, agents abroad monitored service and technical personnel who would implement a nuclear attack so as to be able either to preempt it or have mutually assured destruction. On 1 September 1983, the Soviet military shot down a South Korean passenger jet, Korean Air Lines Flight 007, that had strayed into Soviet airspace. All 269 people aboard the aircraft were killed, including U.S. Representative Larry McDonald and many other Americans. The first Pershing II missiles were delivered to West Germany on 1 December 1983. Bruce G. Blair, an expert on Cold War nuclear strategies and former president of the World Security Institute in Washington, D.C., says the American–Soviet relationship at that time:
== Essendon Football Club == Reid joined Essendon Football club in 1982 shortly after Kevin Sheedy, a player at Richmond, had joined as coach. From this time until his cancer diagnosis in 2018, he served as senior medical officer for Essendon.
Sources: en.wikipedia.org
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.
No. It is a receptor agonist that stimulates the pituitary to release endogenous growth hormone. It does not contain or deliver growth hormone. Its downstream effects therefore depend on a functioning pituitary and an intact signaling pathway.
Pituitary responsiveness, receptor availability, and the natural pulsatility of the growth hormone axis all contribute. Because the compound amplifies an existing release pattern rather than overriding it, timing and physiological state matter. Individual variability in response is well documented but not fully explained.
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.